Treatment involving dkk-1 or antagonists thereof
CA 2438245 A1 · Owner: Genentech, Inc. · Inventors: Stewart, Timothy A.; Dealmeida, Venita I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antagonists to Dickkopf-1 (Dkk-1) proteins are administered in effective amounts to treat disorders involving insulin resistance such as non-insulin-, dependent diabetes mellitus (NIDDM) hypoinsulinemia, and disorders involving muscle atrophy, trauma, or degeneration. Preferably the antagonists are , composed of compositions comprising antibodies directed to Dkk-1 in a pharmaceutically acceptable carrier for use in blocking the effects of Dkk-1. Additionally provided is a method of treating obesity or hyperinsulinemia in a mammal by administering an effective amount of Dkk-1 to a mammal. Also provided are methods of diagnosing insulin resistance hyper- and , hypoinsulinemia, obesity, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.